# A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine

> **NCT03555071** · PHASE3 · COMPLETED · sponsor: **Sinovac (Dalian) Vaccine Technology Co., Ltd.** · enrollment: 1197 (actual)

## Conditions studied

- Varicella

## Interventions

- **BIOLOGICAL:** Vaccine manufactured at commercialized scale
- **BIOLOGICAL:** Vaccine manufactured at trial-scale

## Key facts

- **NCT ID:** NCT03555071
- **Lead sponsor:** Sinovac (Dalian) Vaccine Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-07
- **Primary completion:** 2017-05-20
- **Final completion:** 2017-09-14
- **Target enrollment:** 1197 (ACTUAL)
- **Last updated:** 2018-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03555071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03555071, "A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03555071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*